EUVIMEDEUVIMED entdecken
Crossref

PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes

Yingkun Sheng, Guibing Meng, Zhirong Zhou iD, Ruijiao Du iD, Yuefei Wang, Miaomiao Jiang iD

Molecular Omics · 10.05.2023 · 19 (7) · 560-573

DOI: 10.1039/d3mo00033h ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Omics, online erschienen am 10.05.2023. Verfasst von Yingkun Sheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Component-based Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medici…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Antineoplastic Agents, Atherosclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Tianjin Science and Technology Program, Tianjin Research Innovation Project for Postgraduate Students.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The DNA damage repair enzyme, poly(ADP-ribose) polymerase 1 (PARP1), is crucial for lipid and glucose metabolism. However, no evidence has been presented on the relationship between liver lipid accumulation and the PARP1 inhibitor, 3-aminobenzamide (3-AB), in atherosclerosis.

Methods

ApoE−/− mice were used to explore the effect of 3-AB on atherosclerotic liver lipid accumulation, and the experiment of Sprague Dawley (SD) rats was designed to determine if the lowering of liver lipid levels by 3-AB was linked to gut bacteria. The levels of bile acid metabolism-related targets were assessed by ELISA, western blotting, and RT-qPCR. The relative abundances of gut microbes and biomarkers were determined using 16S rRNA sequencing analysis. Bile acid levels in the liver and ileum were examined by ultra-performance liquid chromatography-tandem mass spectrometry. The relationship between gut microbes and bile acids was assessed by Spearman's correlation analysis.

Results

3-AB significantly reduced the formation of aortic plaques in apoE−/− mice, according to gross oil red staining. H & E and Oil Red O staining revealed that 3-AB significantly reduced the hepatic lipid droplet area in ApoE−/− mice and SD rats. Compared with the atherosclerosis (ATH) group, 3-AB dramatically decreased the levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) in the serum of SD rats and apoE−/− mice, and the levels of TC, TG, and LDL-C in the serum and liver of apoE−/− mice. Furthermore, in apoE−/− mice and SD rats, 3-AB increased the mRNA and protein levels of farnesoid X receptor (FXR) and bile salt export pump (BSEP) in the liver, while inhibiting the mRNA and protein levels of FXR and fibroblast growth factor 15 (FGF15) in the ileum, respectively. 3-AB clearly inhibited the mRNA and protein levels of PARP1 in the liver and ileum of apoE−/− mice and rats. Following treatment with 3-AB, the levels of conjugated bile acids decreased in the liver of apoE−/− mice and increased in the ileum of SD rats, according to targeted metabolomic analysis. Microbiome sequencing analysis revealed that 3-AB reduced the relative abundance of Lactobacillus, Bifidobacterium, Listeria, Clostridium, Bacillus, and Staphylococcus in the feces of apoE−/− mice, and the relative abundance of Blautia, Clostridium, and Listeria in the feces of SD rats, eventually decreasing the total abundance of 10 bile salt hydrolase-associated gut microbes. According to the correlation analysis, 3-AB regulates bile acid metabolism, which is primarily related to Bifidobacterium.

Conclusion

3-AB alleviated atherosclerosis by modulating the bile acid metabolism and bile salt hydrolase-related gut microbes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeAntineoplastic AgentsAtherosclerosisRatsMiceAnimalsPoly(ADP-ribose) Polymerase InhibitorsCholesterol, LDLRNA, Ribosomal, 16SRats, Sprague-DawleyLiverApolipoproteins EBile Acids and Salts

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsCholesterol, LDLRNA, Ribosomal, 16SAntineoplastic AgentsApolipoproteins EBile Acids and Salts

Autor:innen und Institutionen

  • State Key Laboratory of Component-based Chinese Medicine, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Ti…
  • Department of Pharmacy, Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
  • Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China.

ORCID-Profile: Zhirong Zhou, Ruijiao Du, Miaomiao Jiang

Förderung

  • Tianjin Science and Technology Program
  • Tianjin Research Innovation Project for Postgraduate Students

Zitieren

APA

Sheng, Y., Meng, G., Zhou, Z., Du, R., Wang, Y., & Jiang, M. (2023). PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes. Molecular Omics, 19(7), 560-573. https://doi.org/10.1039/d3mo00033h

Vancouver

Sheng Y, Meng G, Zhou Z, Du R, Wang Y, Jiang M. PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes. Molecular Omics. 2023;19(7):560-573. doi:10.1039/d3mo00033h

BibTeX
@article{Sheng2023,
  author = {Sheng, Yingkun and Meng, Guibing and Zhou, Zhirong and Du, Ruijiao and Wang, Yuefei and Jiang, Miaomiao},
  title = {PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes},
  journal = {Molecular Omics},
  year = {2023},
  volume = {19},
  number = {7},
  pages = {560--573},
  doi = {10.1039/d3mo00033h}
}
Kostenlos starten →